USA +1(866) 503.1470 ORDERS@hemaclear.com

Company Profile

OHK Medical Devices

OHK Medical Devices is a privately held Medical Devices Company, manufacturing and selling innovative products for orthopedic surgery, vascular surgery, and emergency medicine. Its core patent-protected technology is a line of single-use devices for quick and effective displacement of blood from the limbs and blocking its re-entry.

OHK’s surgical products – the HemaClear® – are sterile and are widely used to create a bloodless surgical field. Over 1 million procedures have been performed with the HemaClear® on 5 continents, with excellent acceptance by users and an impeccable safety track record.

HemaClear® is endorsed by key opinion leaders in adult and pediatric medical centers worldwide.

OHK recently launched its EED™ product line for use in Emergency Medicine, where it is used to auto-transfuse a patient’s own blood from the limbs into central circulation, during severe shock and during Cardio Pulmonary Resuscitation (CPR).

HemaClear® Single-Use Surgical Tourniquets uniquely combines two key functions:

  • Shifting blood from an extremity (exsanguination)
  • Creating an effective arterial block (tourniquet)

HemaClear® Tourniquets enable OR personnel to obtain a bloodless surgical field within seconds, without the need for any additional equipment.

Studies have shown that the use of HemaClear® Sterile Tourniquets dramatically reduces post-procedure complications.

HemaClear® Tourniquets are available in a wide range of sizes, for both upper and lower extremities, and they fit any patient – from infants to obese adults.

The narrow footprint of the device provides the surgeon with the broadest surgical field, promoting an improved surgical exposure.

HemaClear® is simple to use and reduces OR clutter.

Once applied, HemaClear® Tourniquets provide a 100% Sterile surgical field.

For additional information contact us.

.

HemaClear® was used in over 800,000 procedures around the world on all 5 continents with an impeccable safety track record.

HemaClear® has been used in around 1 million procedures around the world on all 5 continents with an impeccable safety track record.

HemaClear® was used in over 800,000 procedures around the world on all 5 continents with an impeccable safety track record.

Noam Gavriely M.D., D.Sc. – Founder & CMO

Prof. Noam Gavriely completed his M.D. and D.Sc. (cardio-pulmonary physiology) at the Technion – Israel Institute of Technology and his post-doctoral training at the Harvard School of Public Health.

He then headed the Pulmonary Physiology Unit at the Technion until 2006.

In parallel Prof. Gavriely held positions at the Biomedical Engineering and Anesthesia Departments at Northwestern University, Chicago IL.

His clinical background is in emergency medicine as an Israel Defense Force Medical Officer and in Emergency Departments in hospitals in Central Illinois until 2005.

Prof. Gavriely’s academic research focused on cardio-pulmonary acoustics and high-frequency ventilation , and resulted in >70 scientific papers in peer-reviewed journals.
Prof. Gavriely is the Founder of a number of biomedical companies including: Karmel Medical AT Ltd., OHK Medical Devices Ltd., KarmelSonix Ltd., ETview Ltd. and Cardio-Acoustics Ltd.

David L. Helfet, M.D.

Dr. Helfet is currently Professor of Orthopaedic Surgery at Weill Cornell Medical College and Director of the Orthopaedic Trauma Service at both Hospital for Special Surgery and New York-Presbyterian Hospital. Additionally, Dr. Helfet is designated as the Orthopedic Trauma specialist for the Fire Department of New York (FDNY), the New York Police Department (NYPD), and New York State Police and provides advanced orthopedic care to members who are injured in the line of duty.

Dr. Helfet has published extensively on orthopedic trauma topics including numerous articles and book chapters. He frequently presents at both national and international conferences on treatment of orthopaedic trauma. He has received such visiting lectureships as the Presidential Guest and Watson-Jones Memorial Lecture of the British Orthopaedic Association, and has been the recipient of many honors and awards.

John H. Abeles M.D.

Dr. Abeles was born in 1945 in Rhodesia (now Zimbabwe). He received his Medical degree as well as a degree in Pharmacology from the University of Birmingham, England, in 1969.

Dr. Abeles practiced Medicine in London, before joining the Pharmaceutical Industry as a Senior Medical Executive, with Sterling Drug, Pfizer Inc. and Revlon Health Care. In 1975 he became a Wall Street health-care analyst with Kidder Peabody until 1980, when he formed MedVest and later Northlea Partners. Since March 1992, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners Ltd., a private venture and private capital family office headquartered in Boca Raton, Florida. Since 1980, He has also been President of MedVest, Inc., a business and financial consulting firm.

Dr. Abeles has been instrumental in helping promulgate many early stage medical and other companies; some are still private and several have emerged into the public arena. He sits on several private and public company boards.

Dr. Abeles serves as an Advisory Board Member of the College of Chemistry, University of California, Berkeley, and is on the Advisory Board of the Higuchi BioSciences Institute at the University of Kansas. He is a Fellow of the Royal Society of Medicine, London. He is also the Managing Member of Dalyda Finance LLC, a family company engaging promising artistic and performing talent.

Learn About HemaClear®

Pin It on Pinterest

Share This